Articles published by Fractyl Health, Inc.

< Previous 1 2 Next >

Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026

November 06, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization

October 30, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance

October 29, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance

October 22, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation

October 16, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health to Participate in Upcoming September Investor Conferences

September 09, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

August 20, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates

August 10, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026

August 03, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health to Participate in Upcoming Investor Events

July 22, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

July 15, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

June 04, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

June 01, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

May 12, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

May 11, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

May 05, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

March 24, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026

March 17, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance

February 26, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

January 29, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness

January 06, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category

January 05, 2026

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones

December 15, 2025

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

December 02, 2025

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference

December 01, 2025

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027

November 12, 2025

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

November 05, 2025

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

October 07, 2025

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

September 26, 2025

From Fractyl Health, Inc.

Via GlobeNewswire

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

September 26, 2025

From Fractyl Health, Inc.

Via GlobeNewswire

< Previous 1 2 Next >

Articles published by Fractyl Health, Inc.

Starting at /week.